| scholarly article | Q13442814 |
| P2093 | author name string | C Richter King | |
| Douglas E Brough | |||
| Jason G Gall | |||
| Gordon A Byrnes | |||
| Lisa L Wei | |||
| Melissa M Hamilton | |||
| P2860 | cites work | HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses | Q24312224 |
| Age-related eye diseases: an emerging challenge for public health professionals | Q25257145 | ||
| Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization | Q28203561 | ||
| Differential expression of the complement regulatory proteins in the human eye | Q28285403 | ||
| Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment | Q29615852 | ||
| Biochemical and genetic analysis of the Drk SH2/SH3 adaptor protein of Drosophila. | Q30193377 | ||
| Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin | Q30686422 | ||
| AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization | Q31064406 | ||
| Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization | Q31081886 | ||
| Molecular cloning of rat and mouse membrane cofactor protein (MCP, CD46): preferential expression in testis and close linkage between the mouse Mcp and Cr2 genes on distal chromosome 1. | Q31983999 | ||
| Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). | Q32041277 | ||
| Quantitative image analysis of laser-induced choroidal neovascularization in rat. | Q33181304 | ||
| Treatment of diabetic retinopathy | Q33719173 | ||
| Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions | Q33849565 | ||
| a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer | Q33912833 | ||
| Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor | Q34477473 | ||
| Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir | Q34562176 | ||
| Angiogenic gene therapy strategies for the treatment of cardiovascular disease | Q34999146 | ||
| VEGF gene therapy for coronary artery disease and peripheral vascular disease | Q35109285 | ||
| Age-Related Macular Degeneration: Etiology, Pathogenesis, and Therapeutic Strategies | Q35126780 | ||
| Adenovirus Interaction with Its Cellular Receptor CAR | Q35127702 | ||
| Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy | Q35232341 | ||
| Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59. | Q35677703 | ||
| Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses | Q35837026 | ||
| Risks of intravitreous injection: a comprehensive review | Q35922099 | ||
| Minimizing the risk of endophthalmitis following intravitreous injections | Q35922103 | ||
| What does it take to bind CAR? | Q36234462 | ||
| Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review | Q36402000 | ||
| New pharmacologic approaches to therapy for age-related macular degeneration | Q36489172 | ||
| Ranibizumab: Phase III clinical trial results | Q36578530 | ||
| Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration | Q36619213 | ||
| A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. | Q36808087 | ||
| Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41 | Q36976598 | ||
| Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States | Q37015368 | ||
| Is the incidence of registrable age-related macular degeneration increasing? | Q37317621 | ||
| The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F | Q39581053 | ||
| CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. | Q39612847 | ||
| Adenovirus type 11 uses CD46 as a cellular receptor | Q39864028 | ||
| Comprehensive characterization of the 293-ORF6 cell line. | Q40299607 | ||
| Repeated administration of adenovector in the eye results in efficient gene delivery | Q40361858 | ||
| A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities | Q40526341 | ||
| A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer | Q40528468 | ||
| TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors | Q40542132 | ||
| A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer | Q40580007 | ||
| Adenoviral-mediated suicide gene therapy for ovarian cancer | Q40612020 | ||
| A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. | Q40616259 | ||
| Molecular cloning of a murine homologue of membrane cofactor protein (CD46): preferential expression in testicular germ cells | Q41999817 | ||
| Novel role for a complement regulatory protein (CD46) in retinal pigment epithelial adhesion | Q42445154 | ||
| TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up | Q42666208 | ||
| Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. | Q43816068 | ||
| Intraocular adenoviral vector-mediated gene transfer in proliferative retinopathies. | Q43974163 | ||
| Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier | Q44340120 | ||
| Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization | Q44401505 | ||
| Efficient gene transfer into retinal cells using adenoviral vectors: dependence on receptor expression | Q44909595 | ||
| Repeat administration of proteins to the eye with a single intraocular injection of an adenovirus vector | Q45328468 | ||
| TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene | Q45855568 | ||
| Commentary: an aye for eye gene therapy | Q45855698 | ||
| Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector | Q45861664 | ||
| Development of adenovirus serotype 35 as a gene transfer vector | Q45863407 | ||
| In vivo adenovirus-mediated gene transfer into ocular tissues | Q45867135 | ||
| Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. | Q45868863 | ||
| CD46 is a cellular receptor for group B adenoviruses | Q45869560 | ||
| Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo | Q45879004 | ||
| Causes and prevalence of visual impairment among adults in the United States | Q46890945 | ||
| Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial | Q46924646 | ||
| Adenovirus vector-mediated in vivo gene transfer into adult murine retina. | Q54636039 | ||
| Prevalence of Visual Impairment in the United States | Q57099844 | ||
| Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer | Q64379020 | ||
| Adenovirus-mediated gene transfer to murine retinal cells in vitro and in vivo | Q64383505 | ||
| In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector | Q64383564 | ||
| Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group | Q67696853 | ||
| Clinical coxsackievirus B isolates differ from laboratory strains in their interaction with two cell surface receptors | Q73091334 | ||
| Angiogenesis inhibition in age-related macular degeneration | Q73211566 | ||
| Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors | Q74047120 | ||
| Impact of overweight on chronic microvascular complications in type 1 diabetic patients | Q81897787 | ||
| P304 | page(s) | 2535-2546 | |
| P577 | publication date | 2008-12-30 | |
| P1433 | published in | Molecular Vision | Q6895981 |
| P1476 | title | Alternate serotype adenovector provides long-term therapeutic gene expression in the eye | |
| P478 | volume | 14 |
| Q35914367 | A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens |
| Q49963933 | A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy |
| Q34322336 | Characterization of human adenovirus 35 and derivation of complex vectors |
| Q28730757 | Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination |
| Q33558605 | Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization |
| Q39437315 | Getting genetic access to natural adenovirus genomes to explore vector diversity |
| Q42326136 | Improving gene transfer in human renal carcinoma cells: Utilization of adenovirus vectors containing chimeric type 5 and type 35 fiber proteins |
| Q34215308 | Ocular localization and transduction by adenoviral vectors are serotype-dependent and can be modified by inclusion of RGD fiber modifications |
| Q35173777 | Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates? |
| Q27026916 | PEDF and its roles in physiological and pathological conditions: implication in diabetic and hypoxia-induced angiogenic diseases |
| Q90671891 | Pigment Epithelium-Derived Factor as a Possible Treatment Agent for Choroidal Neovascularization |
| Q34081164 | Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. |
| Q58753310 | Targeting CD46 Enhances Anti-Tumoral Activity of Adenovirus Type 5 for Bladder Cancer |
| Q36016455 | Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity |
| Q37624973 | Type I interferon-dependent activation of NK cells by rAd28 or rAd35, but not rAd5, leads to loss of vector-insert expression |
| Q34561531 | Vector platforms for gene therapy of inherited retinopathies. |
Search more.